Planejamento e s?ntese de compostos ftalazoilidraz?nicos como agentes anti-TNF-?
Ano de defesa: | 2013 |
---|---|
Autor(a) principal: | |
Orientador(a): | |
Banca de defesa: | , |
Tipo de documento: | Dissertação |
Tipo de acesso: | Acesso aberto |
Idioma: | por |
Instituição de defesa: |
Universidade Federal Rural do Rio de Janeiro
|
Programa de Pós-Graduação: |
Programa de P?s-Gradua??o em Qu?mica
|
Departamento: |
Instituto de Ci?ncias Exatas
|
País: |
Brasil
|
Palavras-chave em Português: | |
Palavras-chave em Inglês: | |
Área do conhecimento CNPq: | |
Link de acesso: | https://tede.ufrrj.br/jspui/handle/jspui/3428 |
Resumo: | Many classes of organic compounds have shown promising biological effects, and among them are the cyclic imides, compounds that have on their structure the fragment CO-N(R)-CO-, in which R is a hydrogen atom, an alkyl or an aryl group. The phthalimides,that have recognized biological activity, are compounds related to thalidomide, a molecule with structure derived from phthalimide, but also presents a glutarim?dic group, being considered the most relevant molecule that belongs to this class of compounds. The phthalimidic ring is related as an interesting biophore, constituting a subunity structure of pharmacophore character for a series of compounds with different pharmacological activities, including the anti-inflammatory, according to a mechanism of inhibition of tumor necrosis factor alpha (TNF-?), a pro-inflammatory cytokine. Due to the side effects associated to current medications anti-TNF-?, that belong exclusively to the class of biotech drugs, and the high cost of treatment, the discovery of new anti-inflammatory micromolecules that act inhibiting the production of TNF-? is important. In this context, one of the first described molecules with this activity was thalidomide, whose pharmacological action is attributed to the phthalimidic group. in this work N-hydrazil substituted phthalimides, the phthalazoylidrazides were synthesized, charatered and tested for biological activity. These compounds were synthesized from benzoic acids and corresponding aldehydes, that were transformed into methyl esters. Subsequent hydrazinolysis reaction, with hydrazine hydrate, provided the corresponding hydrazides that, after, reacted with phthalic anhydride in order to form the phthalimidic ring. This initial series was still methylated by reaction with methyl iodide in basic medium. The synthesis of phthalazoylidrazides N-methylated and non-methylated intent to analyze the effect of the presence of the methyl group on the possible biological activity of the compounds, because it is known that the methyl group exerts estereoeletr?nic effects over biomolecules that can lead to significant changes in biological effects of molecules. 22 final compounds were synthesized with yields between 58% and 96%. The pharmacological analysis showed that some methylated derivatives were able to inhibit the production of TNF-? in experiments with macrophages stimulated by LPS. The activity presented shows the biological importance of phthalimides and N-methylation in this series. Furthermore, the synthesis proposal proved adequate and practical using microwave irradiation. |
id |
UFRRJ-1_8d6f379c120e24a4983f451971033050 |
---|---|
oai_identifier_str |
oai:localhost:jspui/3428 |
network_acronym_str |
UFRRJ-1 |
network_name_str |
Biblioteca Digital de Teses e Dissertações da UFRRJ |
repository_id_str |
|
spelling |
K?mmerle, Arthur Eugen053.978.487-78http://lattes.cnpq.br/5598000938584486Graebin, Cedric StephanMiranda, Leandro S. M.002.022.197-55http://lattes.cnpq.br/0126796004403127Teixeira, F?bio Barbosa2020-04-09T23:25:12Z2013-03-07TEIXEIRA, F?bio Barbosa. Planejamento e s?ntese de compostos ftalazoilidraz?nicos como agentes anti-TNF-?. 2013. 192 f. Disserta??o (Mestrado em Qu?mica) - Instituto de Ci?ncias Exatas, Universidade Federal Rural do Rio de Janeiro, Serop?dica, 2013.https://tede.ufrrj.br/jspui/handle/jspui/3428Many classes of organic compounds have shown promising biological effects, and among them are the cyclic imides, compounds that have on their structure the fragment CO-N(R)-CO-, in which R is a hydrogen atom, an alkyl or an aryl group. The phthalimides,that have recognized biological activity, are compounds related to thalidomide, a molecule with structure derived from phthalimide, but also presents a glutarim?dic group, being considered the most relevant molecule that belongs to this class of compounds. The phthalimidic ring is related as an interesting biophore, constituting a subunity structure of pharmacophore character for a series of compounds with different pharmacological activities, including the anti-inflammatory, according to a mechanism of inhibition of tumor necrosis factor alpha (TNF-?), a pro-inflammatory cytokine. Due to the side effects associated to current medications anti-TNF-?, that belong exclusively to the class of biotech drugs, and the high cost of treatment, the discovery of new anti-inflammatory micromolecules that act inhibiting the production of TNF-? is important. In this context, one of the first described molecules with this activity was thalidomide, whose pharmacological action is attributed to the phthalimidic group. in this work N-hydrazil substituted phthalimides, the phthalazoylidrazides were synthesized, charatered and tested for biological activity. These compounds were synthesized from benzoic acids and corresponding aldehydes, that were transformed into methyl esters. Subsequent hydrazinolysis reaction, with hydrazine hydrate, provided the corresponding hydrazides that, after, reacted with phthalic anhydride in order to form the phthalimidic ring. This initial series was still methylated by reaction with methyl iodide in basic medium. The synthesis of phthalazoylidrazides N-methylated and non-methylated intent to analyze the effect of the presence of the methyl group on the possible biological activity of the compounds, because it is known that the methyl group exerts estereoeletr?nic effects over biomolecules that can lead to significant changes in biological effects of molecules. 22 final compounds were synthesized with yields between 58% and 96%. The pharmacological analysis showed that some methylated derivatives were able to inhibit the production of TNF-? in experiments with macrophages stimulated by LPS. The activity presented shows the biological importance of phthalimides and N-methylation in this series. Furthermore, the synthesis proposal proved adequate and practical using microwave irradiation.Muitas classes de compostos org?nicos t?m demonstrado promissores efeitos biol?gicos, dentre elas as imidas c?clicas, compostos que apresentam na estrutura o grupo ?CO-N(R)-CO-, sendo R um ?tomo de hidrog?nio, um grupo alquila ou um grupo arila. As ftalimidas, que apresentam conhecida atividade biol?gica, s?o compostos que t?m sua hist?ria relacionada ? talidomida, mol?cula que possui estrutura derivada da ftalimida, mas apresenta tamb?m um grupamento glutarim?dico, podendo ser considerada a mol?cula mais relevante pertencente a esta classe de compostos. O anel ftalim?dico ? relatado como um interessante bi?foro, constituindo subunidade estrutural de car?ter farmacof?rico para uma s?rie de compostos com diferentes atividades farmacol?gicas, dentre elas a anti-inflamat?ria, segundo um mecanismo de inibi??o do fator de necrose tumoral alfa (TNF-?), uma citocina pr?-inflamat?ria. Devido aos efeitos colaterais associados aos atuais medicamentos anti-TNF-?, que pertencem exclusivamente a classe dos f?rmacos biotecnol?gicos, e ao alto custo do tratamento, ? importante a descoberta de novas micromol?culas anti-inflamat?rias que atuem pela inibi??o da produ??o do TNF-?. Neste contexto, uma das primeiras mol?culas descrita com esta atividade foi a talidomida, cuja a??o farmacol?gica ? atribu?da ao grupo ftalim?dico. Em fun??o da confirmada atividade anti TNF-? das ftalimidas funcionalizadas, neste trabalho foi realizada a s?ntese, caracteriza??o e verificada da atividade de ftalimidas N-hidrazil substitu?das, as ftalazoilidrazidas. Estes compostos foram sintetizados a partir dos ?cidos benz?icos e alde?dos correspondentes, que foram transformados em ?steres met?licos. Subsequente rea??o de hidrazin?lise, com hidrazina hidrato, forneceu as hidrazidas correspondentes que foram posteriormente reagidas com anidrido ft?lico, a fim de formar o anel ftalim?dico. Esta s?rie inicial foi ainda metilada por rea??o com iodeto de metila em meio b?sico. A s?ntese de ftalazoilidrazidas n?o-metiladas e N-metiladas tem como finalidade a an?lise do efeito da presen?a do grupo metila na poss?vel atividade biol?gica dos compostos, pois ? sabido que o grupo metila exerce efeitos estereoeletr?nicos sobre as biomol?culas que podem levar a mudan?as significativas nos efeitos biol?gicos das mol?culas. Foram sintetizados 22 compostos finais com rendimentos entre 58% e 96%. A an?lise farmacol?gica dos mesmos mostrou que alguns derivados metilados forram capazes de inibir a produ??o de TNF-? em ensaios com macr?fagos estimulados por LPS. A atividade apresentada mostra a import?ncia biol?gica das ftalimidas e da N-metila??o nesta s?rie. Ademais, a s?ntese proposta mostrou-se adequada e pr?tica, com a utiliza??o de irradia??o em microondas.Submitted by Sandra Pereira (srpereira@ufrrj.br) on 2020-04-09T23:25:11Z No. of bitstreams: 1 2013 - Fabio Barbosa Teixeira.pdf: 5317223 bytes, checksum: e12b482db3dc946929ea05fabb52b921 (MD5)Made available in DSpace on 2020-04-09T23:25:12Z (GMT). No. of bitstreams: 1 2013 - Fabio Barbosa Teixeira.pdf: 5317223 bytes, checksum: e12b482db3dc946929ea05fabb52b921 (MD5) Previous issue date: 2013-03-07application/pdfhttps://tede.ufrrj.br/retrieve/64416/2013%20-%20F%c3%a1bio%20Barbosa%20Teixeira.pdf.jpgporUniversidade Federal Rural do Rio de JaneiroPrograma de P?s-Gradua??o em Qu?micaUFRRJBrasilInstituto de Ci?ncias ExatasAbbas, A., K.; Lichtman, A., H.; Pillai, S., (trad. Farias, A., S.); Imunologia Celular e Molecular, 6? ed., Elsevier, Rio de Janeiro, 2008. Akgun, H.; Karamelekoglu, I.; Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry: Recent Developments of Thalidomide Derivatives Possessing Anti-Inflammatory Activity, 9, 71-81, 2010. Akgun, H.; Karamelekoglu, I.; Berk, B.; Kurnaz, I.; Sarbyk, G.; Bioorg. Med. Chem: Synthesis and anti-mycobacterial activity of some phthalimide derivatives, 20, 4149-4154, 2012. Almeida, M. V.; Teixeira, F. M.; Souza de, M. V. N.; Amarante, G. W.; Alves, C. C. S.; Cardoso, S. H.; Mattos. A. M.; Ferreira, A. P.; Teixeria, H. C.; Chem Pharm Bull.: Thalidomide Analogs from Diamines: Synthesis and Evaluation as Inhibitors of TNF-? Production, 55, 2, 223-227, 2007. Andricopulo, A., D.; Filho, A., W.; Corr?a, R.; Santos, A., R., S.; Nunes, R., J.; Yunes, R., A.; Cechinel Filho, V.; Pharmazie, 53, 493, 1998. Antunes, R.; Batista, H.; Srivastra, R., M.; Thomas, G.; Ara?jo, C., C.; Bioorg. Med. Chem. Lett, 8, 3071, 1998. Back M. E.; Mandarino J. A. Fleischer?s glossary of Mineral Species. Tucson: The Mineralogical Record, 343. 2008. Barreiro, E.J.; Fraga, C.A.M. Qu?mica Medicinal: As Bases Moleculares da A??o dos F?rmacos, 2? edi??o, ARTMED, Porto Alegre, 2008. Barreiro. E.J. Estrat?gia de Simplifica??o Molecular no Planejamento Racional de F?rmacos: A Descoberta de Novo Agente Cardioativo, Quim. Nova, 25, 1172-1180, 2002. Blanchard, B. J.; Chen, A.; Rozeboom, L. M.; Stafford, K. A.; Weigele, P.; Ingram, V. M. Proc. Natl. Acad. Sci. U.S.A., 101, 14326, 2004. Buchanan, G.R.; Debaun, M.R.; Quinn, C.T.; Steinberg, H. Hematology: Sickle cell disease. 35-47, 2004. Burger, A. Burger?s Medicinal Chemistry, 4th ed, Willey, Nova York, 1980. Buzzi, F., C.; Corr?a, R.; Cechinel Filho, V.; In: Ci?ncias Farmac?uticas: Contribui??o ao desenvolvimentpo de novos f?rmacos e medicamentos, Itaja?: Univali, cap.2, p. 59-105, 2003. Campos, F., B.; Corr?a, R.; Cechinel Filho, V.; S?ntese de Mol?culas Bioativas: o exemplo das imidas c?clicas, In: Ci?ncias Farmac?uticas: Contribui??o ao desenvolvimentpo de novos f?rmacos e medicamentos, Itaja?: Univali, p. 57-105, 2000. Cechinel Filho, V.; Corr?a, R.; Nunes, R., J.; Calixto, J., B.; Yunes, R., A.; Pharm. Sci., 1, 399, 1995. Cechinel Filho, V.; Qu?m. Nova: Principais avan?os e perspectivas na ?rea de produtos naturais ativos: estudos desenvolvidos no NIQFAR/UNIVALI, 25 (3), p. 680-685, 2000. Cechinel Filho, V.; Campos, F. de; Yunes, R., A.; Corr?a, R.; Nunes, R., J.; Qu?m. Nova: Aspectos Qu?micos e Potencial Terap?utico de Imidas C?clicas: uma revis?o da literatura, V. 6, n? 2, p. 230-241, 2003. Chu, K. C.; The Basis of Medicinal Chemistry: The quantitative analysis of structure-activity- relationships, New York, Jonh Wiley, 393-418, 1980 Chudler, E., H.; Anderson, L., C.; Archives of Oral Biology: Behavioral and Eletrophisiological Consequences of deafferentation following chronic constriction of the infraorbital nerve in adult rats, v. 47, p. 165-172, 2002. Costa, B. B. C.; Corr?a, R.; Souza M. M. de; Pretto, J. B.; Ardenghi, J. V.; Campos-Buzzi, F. de; Cechinel-Filho, V.; Z Naturforsch: Antinociceptive Effects of Tetrahidrophthalimides and Related Compounds, 62, 201-206, 2007. Cotran, R., S.; Kumar, V.; Collins, T.; (trad. Barbosa, J., B.; De Vasconcelos, M., M.; Voeux, P., J.; Robbins ? Patologia Estrutural e Funcional, 6? ed., Guanabara Koogan, Rio de Janeiro, 2000. Coutaux, A.; Adam, F.; Willer, J., C.; Chelly, J., E.; Joint Bone Spine: Hyperalgesia and allodynia: peripheral mechanisms, v. 72, p. 359-371, 2005. Cunha, F., Q.; Br. J. Pharmacol.: Interleukine-8 as a mediator of symphatetic pain; v. 104, n?3, p. 765-767, 2000. Davies, F., E.; Raje, N., E.; Hideshima, T.; Lentzsch, S.; Young., G.; Tai, Y., T.; Lin, B.; Podar, K.; Gupta, D.; Chauhan, D.; Treon, S., P.; Richardson, P., G.; Schlossman, r., l.; Morgan, G., J.; Muller, G., W.; Stirling, D., I.; Anderson, K., C.; Blood, 98, 210, 2001. Decker L.; Ambrust W.; Rademaker C. M.; Prakken B.; Kuis W.; Wulffraat N. M.; Clin Exp Rheumatol: Safety of anti-TNF therapy in children with juvenile idiopathic arthritis, 22, 252-258, 2004. Dickenson, A., H.; Matthews, E., A.; Suzuki, R.; European Journalof Pain: Neurobiology of neuropathic pain: mode of action of anticonvulsants, v. 6, suplemento A, p. 51-60, 2002. Foeldvari, I.; Krueger, E.; Scneider, T.; Ann. Rheum. Dis.:Acute, non obstructive, steril colecystitis associated with etanercept and infliximab for the treatment of juvenile poliarticular rheumatoid arthritis, 62, 908-909, 2003. Furgeson, D., Y.; Dreher, M., R.; Chilkoti; J. Control. Rel.: Structural optimization of a ?smart? doxorubicin-poypeptide conjugate for thermally targeted delivery to solid tumors, v. 110, p. 362-369, 2006. Furler, R. L.; Uittenbogaart, C. H.; Immunologic Research: Signaling through the P38 and ERK pathways: Acommon link between HIV replication and the immune response, 48, 99-109, 2010. Hargreaves, M., K.; Pritchard, J., G.; Dave, H., R.; Chem. Rev., 70, 439, 1970. Hashimoto, Y.; Curr. Med. Chem, 5, 63, 1998. Hennessy, E. J.; Buchwald, S. L.; J. Org. Chem: Synthesis of 4,5-Dianilinophthalimide and Related Analogues for Potential Treatment of Alzheimer?s Disease via Palladium-Catalyzed Amination, 70, 7371-7375, 2005. Horvat, M.; Uzelac, L.; Marjanovic, M.; Cindro, N.; Frankovic, O.; Kralj, M.; Basaric, N.; Mlinaric-Majerski, K.; Chem Biol, Drug Des.: Evaluation of Antiproliferative Effect of N-(alkyladamantyl)phthalimides In Vitro, 79, 497-506, 2012. Iwai, Y.; Takahashi, H.; Hatakeyama, D.; Motoshima, K.; Ishikawa, M.; Sugita, K.; Hashimoto, Y.; Harada, Y.; Itamura, S.; Odagiri, T.; Tashiro, M.; Sei, Y.; Yamaguchi, K.; Kuzuhara, T.; Bioorg. Med. Chem.: Anti-influenza Activity of Phenetylphntylphthalimide analogs Derived from Thalidomide, 18, 5379-5390, 2010. Kaipiaienen-Seppanen, O.; Leino, M.; Ann Rheum. Dis.: Recurrent uveitis in a pacient with juvenile spondyloarthropathy associated with tumor necrosis factor alfa inhibitors, 62, 88-89, 2003. Kamal, A., Laxman, E., Rao, N. V., Tetrahedron Lett, 39, 8733, 1998. Kaminski, K.; Obniska, J.; Wiklik, B.; Atamanyuk, D.; Eur. J. Med. Chem.: Synthesis and Anticonvulsant Properties of New Acetamide Derivatives of Phthalimide, and its Saturated Ciclohexane and Norbornene Analogs, 46, 4634-4641, 2011. Kappe, C. O.; Stadler, A.; Microwaves in Organic and Medicinal Chemistry, Wiley-VHC, Weinheim, 2005. Kelsey, F., O.; Teratology, 38, 221, 1988. Komoda, M.; Kakuta, H.; Takahashi, H.; Fujimoto, Y.; Kadoya, S.; Kato, F.; Hashimoto, Y.; Bioorg. Med. Chem.: Specific inhibitor of puromycin-sensitive aminopeptidase with a hommophtalimide skeleton: identification of a target molecule and a strucuture- activity relationship study, 9 (1), p. 121-131, 2001. K?mmerle, A.E., Schmitt, M., Cardozo, S.V.S., Lugnier, C., Villa, P., Lopes, A.B., Romeiro, N.C., Justiniano, H., Martins, M.A., Fraga, C.A.M., Bourguignon, J.-J., Barreiro, E.J, J. Med. Chem: Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors, 7525-7545, 2012. K?mmerle, A.E., Raimundo, J.M., Leal, C.M., da Silva, G.S., Balliano, T.L., Pereira, M.A., de Simone, C.A., Sudo, R.T., Zapata-Sudo, G., Fraga, C.A.M., Barreiro, E.J., Eur. J. Med. Chem.:Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives, 44, 4004-4009, 2009. Lakowicz, J. R. In Principles of Fluorescence Spectroscopy, 2? ed., Kluwer Academic/Plenum Publishers, New York, 1999. Lanaro, C.; Franco-Penteado, C. F.; Albuquerque, D. M.; Saad, S. T.; Conran, N.; Costa, F. F; Biol.: Altered Levels of cytokines and inflammatory mediators in plasma and lecocytes of sickle cell anemia patients and effects of hydroxyurea therapy, 85, 2, 235-242, 2009. Lenz, W.; Lancet, 1, 271, 1962. Lima L. M. Planejamento, s?ntese e avalia??o farmacol?gica de novos candidatos ? prot?tipos de f?rmacos antiinflamat?rios e antiasm?ticos . [Tese] Rio de Janeiro: Instituto de Qu?mica, Universidade Federal do Rio de Janeiro, 2001. Lima L. M.; Castro P.; Machado A. L.; Fraga C. A. M.; Lugnier C,; Moraes V. L. G.; Barreiro E. J.; Bioorg Med Chem: Synthesis and anti inflamatory activity of phtalimide derivates, designed as new thalidomids analogues,10, 3067-3073, 2002. Lima L. M.; Fraga C. A. M.; Koatz, V. L. G.; Barreiro E. J.; Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry: Thalidomide and Analogs as Anti-Inflammatory and Immunomodulator Drug Candidates, 5, 79-95, 2006. Lovell, D., J.; Giannini, H., E.; Reiff, A.; Arthritis Reum.: long term efficacy anfd safety of etanercept in children with poliarticular course juvenile rheumatoid arthritis, 48, 218-226, 2003. Lima, P.C.; S?ntese e Avalia??o das propriedades Antinociceptivas de Novas Acilidrazonas Derivadas do Safrol, Rio de Janeiro, 1998. Disserta??o (Mestrado em Qu?mica Org?nica)-IQ, UFRJ, 1998. Luengo, M., B.; Rev. Eletr?n. Farm., 2, 64, 2005. Machado, A., L.; Lima, L., M.; Ara?jo-Jr; Bioorg. Med. Chem: Designing, synthesis and Antiinflamatory activity of novel phtalimide derivatives, structurally related to thalidomide, v. 15, p. 1169-1172, 2005. Madigan; Raj; Br. Med.: Post traumatic pain syndromes, v. 288, p. 169-170, 2000. Malav?, I.; Perdomo, Y.; Escalona, E.; Rodriguez, E.; Anchustegui, M.; Malav?, H. Acta Haematol: Level of Tumor Necrosis Factor alpha/cachectin (TNF alpha) in sera from patients with sickle cell disease. v. 90, 172-176, 1993. McBride, W., G.; Lancet, 2, 1358, 1961. Mellin, G. W.; Katzenstein, M.; Engl .J. Med.: The Saga of Thalidomide, 267, 1184-1193, 1962. Menegatti, R.; Fraga, C., A., M.; Barreiro, E. J.; Quim. Nova Escola: A import?ncia da s?ntese de f?rmacos, 3, p. 16-22, 2001. Neves P. C. P. das; Schenato F.; Bachi F. A. Introdu??o ? Mineralogia Pr?tica. Canoas, ULBRA, 326, 2008. Newman, D. J.; Cragg, G. M.; Snader, K. M.; J. Nat. Prod: Natural Products as Sources of New Drugs over the Period 1981-2002, 66, 1022-1037, 2003. Oh, S.; Kim, J. S.; Hwang, J. H.; Lee, H. Y.; Ryu, M. J.; Park, J.; Kim, S. J.; Jo, Y. S.; Kim, Y. K.; Lee, C.; Kweon, K. R.; Shong, M.; Park, S. B.; J. Med. Chem.: Antidiabetic and Antiobesity Effects of Ampikinone (6f), a Nove Smalll Molecule Ativator of AMP-Actuvated Protein Kinase, 53, 7405-7413, 2010. Olsen, N., J.; Stein., M., C.; New Eng. J.Med.: New drus for Rheumatoid Arthritis, 350, 2167-2179, 2004. Otani, Y.; Nagae, O.; Naruse, Y.; Inagaki, S.; Ohno, M.; Yamaguchi, K.; Yamamoto, G.; Uchiyama, M.; Ohwada, T.; J. Am. Chem. Soc: An Evaluation of Amide Group Planarity in 7-Azabicyclo[2.2.1]heptane Amides. Low Amide Bond Rotation Barrier in Solution, 125, 15191-15199, 2003. Pathare, A.; Kindi, S. A.; Daar, S.; Dennison, D.; Hematology: Cytokines in sickle cell disease, 8, 5, 329-337, 2003. Pfizenmaier, K.; Wajant, H.; Grell, M.; Cytokine Growth Factor Rev., 7, 22, 1996. Poli, G.; Kinter, A.; Justement, J. S.; Proc. Nat. Acad. Sci : Tumor Necrosis Factor Alpha functions in an Autocrine Manner in the Induction of Human Immunodeficiency Virus Expression, 87, 782-785, 1990. Poupaert, J., H.; Gaetane, H.; Barbeaux, P.; Lambert, D.; Henichart, J.; Pharmacology, 47, 89, 1995. Quartier, P.; Taupin, P.; Bourdeaut, F, et al; Arthritis Rheum.: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the Onset Type, 48, 93-101, 2003. Raje, N.; Anderson, K.; New England J. Med., 341, 1606, 1999. Ramanan, A., V.; Scheneder, R.; J. Rheumatol: Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile arthritis, 30, 401-403, 2003. Rang, H., P.; Dale, M., M.; Ritter, J., M.; Flower, R., J. (trad. Do Nascimento, A., P.); Farmacologia, 6? ed., Elsevier, Rio de Janeiro, 2007. Rendall, T., J.; Am. J. Med. Assoc., 263, 1467, 1990. Saldanha, P. H.; Rev.Bras. Genet.: A Trag?dia da Talidomida e o Advento de Teratologia Experimental, 17, 4, 449-464, 1994. Sampaio, E., P.; Zmuidinas, A.; Frindt, P.; Smith, K., A.; Kaplan, G.; J. Exp. Med., 177, 1675, 1993. Seri-Levy, A.; Richards, G.; Tetrahedron Asymmetry, 4, 1917, 1993. Sheskin, J.; Clin. Pharm. Ther., 6, 303, 1965. Shibata, Y., Sasaki, K.; Nishimura, K.; Hashimoto, Y.; Iwasaki, S.; Biol. Pharm. Bull., 17, 1532, 1994. Shibata, Y.; Sasaki, K.; Hashimoto, Y.; Iwasaki, S.; Biol. Pharm. Bull., 18, 1228, 1995. Silverman, R., B.; The Organic Chemistry of Drug Design and Drug Action, 2nd ed., Ed., Elsevier Academic Press, San Diego, 2004. Solomons, C. T. W.; Fryhle, C. B.; Qu?mica Org?nica, LTC editora,Rio de Janeiro, 2000. Sthepens, M., C.; Shepanski, M., A.; Mamula, P.; Markowitz, J., E.; Brown, K., A.; Baldassano, R., N.; Am. J. Gastroenterol., 98, 104-111, 2003. Tamura, F.; Volgesang, G. B.; Reitz, B. A.; Baumgartner, W. A.; Herskovitz, A.; Transplantation: Combination Thalidomide and Ciclosporine for Cardiac Allograft Rejection, 49, 20-25, 1990. Teixeira, F. B. S?ntese ?one-pot?, em microondas, de N-metilidrazidas como intermedi?rios de produtos bioativos. Rio de Janeiro, 2010, Monografia, ICE-DQ, UFRRJ, 2010. Tsuji, M.; Koiso, Y.; Takahashi, H.; Hashimoto, Y.; Endo, Y.; Biol. Pharm. Bull., 23, 513, 2000. Tutar, E.; Eriki, F.; Na?ar, N.; Arici, S.; Atalay, S.; Rheumatology, 43, 674-675, 2004. Tweedie, D.; Luo, W.; Short, R., G.; Brossi, A.; Holloway, H., W.; Li, Y.; Yu, Q., S.; Greig, N., H.; J. Neurosci. Meth.: A cellular model of inflammation for identifying TNF-alphasynthesis inhibitors, 183, 182-187, 2009. Verschuren W.G., Dierynck I., Amssoms K. I. E., Hu L., Boonants P. M. J. G., Pille G. M. E., Daeyert F. F. D., Hertogs K , Surleraux D. L. N. G, Wigerinck P. B. T. P. . J Med.Chem.: Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase, 48(6):1930-1940, 2005. Volgesang, G. B.; Wells, M. C.; Santos, G. W.; Chen T. L.; Hess, A. D.; Transplant Proc.: Combination Low-dose Thalidomide and Ciclosporine Prophylaxis for Acute Graft-versus-Host-Disease iin Rat Mismatched Model, 20, 226-228, 1988. Warkany, J.; Year Med. Book Pub.:Congenital Malformations (Notes and Comments), Chicago, 49-129, 1971. Weiberg, K.; Acc Chem. Res.: The Interaction of Carbonil Groups with Substituents, 32, 922-929, 1999. Wermuth, C., G; The Practice of Medicinal Chemistry, Ed., Academic Press, Londres, 2008. Wermuth, C.G. & Langer, T.; Pharmacophore identification, em 3D QSAR in Drug Design. Theory Methods and application, Kubinyi, H., Ed., ESCOM, Leiden, pp. 117-136, 1993. Wettstein, A. R.; Meagher, A. P.; Lancet: Thalidomide in Chron`s Disease,350, 1445-1446, 1997. Yamada, S.; Morizono, D.; Yamamoto, K. Tetrahedron Lett: Mild Oxidation of Aldehydes to the Coresponding Carboxylic Acids and Esters: Alkaline Iodine Oxidation Revisited, 33, 4329-4332, 1992.Ftalimidasatividade anti-TNF-?inflama??oPhthalimidesanti-TNF-? activityinflammationQu?micaPlanejamento e s?ntese de compostos ftalazoilidraz?nicos como agentes anti-TNF-?Planning and synthesis of phthalazoilidrazynic compounds aiming anti-TNF-? agentsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da UFRRJinstname:Universidade Federal Rural do Rio de Janeiro (UFRRJ)instacron:UFRRJTHUMBNAIL2013 - F?bio Barbosa Teixeira.pdf.jpg2013 - F?bio Barbosa Teixeira.pdf.jpgimage/jpeg2721http://localhost:8080/tede/bitstream/jspui/3428/8/2013+-+F%C3%A1bio+Barbosa+Teixeira.pdf.jpg5ac00e5dadea4a97435967a50f95959cMD58ORIGINAL2013 - F?bio Barbosa Teixeira.pdf2013 - F?bio Barbosa Teixeira.pdfapplication/pdf6031231http://localhost:8080/tede/bitstream/jspui/3428/6/2013+-+F%C3%A1bio+Barbosa+Teixeira.pdfb329ffba7061b0158a4f1fae7d46dbc9MD56TEXT2013 - Fabio Barbosa Teixeira.pdf.txt2013 - Fabio Barbosa Teixeira.pdf.txttext/plain147021http://localhost:8080/tede/bitstream/jspui/3428/3/2013+-+Fabio+Barbosa+Teixeira.pdf.txte0d3e99cd599c6168d530961343a90afMD532013 - F?bio Barbosa Teixeira.pdf.txt2013 - F?bio Barbosa Teixeira.pdf.txttext/plain146437http://localhost:8080/tede/bitstream/jspui/3428/7/2013+-+F%C3%A1bio+Barbosa+Teixeira.pdf.txt378d4a30e599f29fa54a651742682aceMD57LICENSElicense.txtlicense.txttext/plain; charset=utf-82089http://localhost:8080/tede/bitstream/jspui/3428/1/license.txt7b5ba3d2445355f386edab96125d42b7MD51jspui/34282022-09-22 14:23:16.06oai:localhost:jspui/3428Tk9UQTogQ09MT1FVRSBBUVVJIEEgU1VBIFBSP1BSSUEgTElDRU4/QQpFc3RhIGxpY2VuP2EgZGUgZXhlbXBsbyA/IGZvcm5lY2lkYSBhcGVuYXMgcGFyYSBmaW5zIGluZm9ybWF0aXZvcy4KCkxJQ0VOP0EgREUgRElTVFJJQlVJPz9PIE4/Ty1FWENMVVNJVkEKCkNvbSBhIGFwcmVzZW50YT8/byBkZXN0YSBsaWNlbj9hLCB2b2M/IChvIGF1dG9yIChlcykgb3UgbyB0aXR1bGFyIGRvcyBkaXJlaXRvcyBkZSBhdXRvcikgY29uY2VkZSA/IFVuaXZlcnNpZGFkZSAKWFhYIChTaWdsYSBkYSBVbml2ZXJzaWRhZGUpIG8gZGlyZWl0byBuP28tZXhjbHVzaXZvIGRlIHJlcHJvZHV6aXIsICB0cmFkdXppciAoY29uZm9ybWUgZGVmaW5pZG8gYWJhaXhvKSwgZS9vdSAKZGlzdHJpYnVpciBhIHN1YSB0ZXNlIG91IGRpc3NlcnRhPz9vIChpbmNsdWluZG8gbyByZXN1bW8pIHBvciB0b2RvIG8gbXVuZG8gbm8gZm9ybWF0byBpbXByZXNzbyBlIGVsZXRyP25pY28gZSAKZW0gcXVhbHF1ZXIgbWVpbywgaW5jbHVpbmRvIG9zIGZvcm1hdG9zID91ZGlvIG91IHY/ZGVvLgoKVm9jPyBjb25jb3JkYSBxdWUgYSBTaWdsYSBkZSBVbml2ZXJzaWRhZGUgcG9kZSwgc2VtIGFsdGVyYXIgbyBjb250ZT9kbywgdHJhbnNwb3IgYSBzdWEgdGVzZSBvdSBkaXNzZXJ0YT8/byAKcGFyYSBxdWFscXVlciBtZWlvIG91IGZvcm1hdG8gcGFyYSBmaW5zIGRlIHByZXNlcnZhPz9vLgoKVm9jPyB0YW1iP20gY29uY29yZGEgcXVlIGEgU2lnbGEgZGUgVW5pdmVyc2lkYWRlIHBvZGUgbWFudGVyIG1haXMgZGUgdW1hIGM/cGlhIGEgc3VhIHRlc2Ugb3UgCmRpc3NlcnRhPz9vIHBhcmEgZmlucyBkZSBzZWd1cmFuP2EsIGJhY2stdXAgZSBwcmVzZXJ2YT8/by4KClZvYz8gZGVjbGFyYSBxdWUgYSBzdWEgdGVzZSBvdSBkaXNzZXJ0YT8/byA/IG9yaWdpbmFsIGUgcXVlIHZvYz8gdGVtIG8gcG9kZXIgZGUgY29uY2VkZXIgb3MgZGlyZWl0b3MgY29udGlkb3MgCm5lc3RhIGxpY2VuP2EuIFZvYz8gdGFtYj9tIGRlY2xhcmEgcXVlIG8gZGVwP3NpdG8gZGEgc3VhIHRlc2Ugb3UgZGlzc2VydGE/P28gbj9vLCBxdWUgc2VqYSBkZSBzZXUgCmNvbmhlY2ltZW50bywgaW5mcmluZ2UgZGlyZWl0b3MgYXV0b3JhaXMgZGUgbmluZ3U/bS4KCkNhc28gYSBzdWEgdGVzZSBvdSBkaXNzZXJ0YT8/byBjb250ZW5oYSBtYXRlcmlhbCBxdWUgdm9jPyBuP28gcG9zc3VpIGEgdGl0dWxhcmlkYWRlIGRvcyBkaXJlaXRvcyBhdXRvcmFpcywgdm9jPyAKZGVjbGFyYSBxdWUgb2J0ZXZlIGEgcGVybWlzcz9vIGlycmVzdHJpdGEgZG8gZGV0ZW50b3IgZG9zIGRpcmVpdG9zIGF1dG9yYWlzIHBhcmEgY29uY2VkZXIgPyBTaWdsYSBkZSBVbml2ZXJzaWRhZGUgCm9zIGRpcmVpdG9zIGFwcmVzZW50YWRvcyBuZXN0YSBsaWNlbj9hLCBlIHF1ZSBlc3NlIG1hdGVyaWFsIGRlIHByb3ByaWVkYWRlIGRlIHRlcmNlaXJvcyBlc3Q/IGNsYXJhbWVudGUgCmlkZW50aWZpY2FkbyBlIHJlY29uaGVjaWRvIG5vIHRleHRvIG91IG5vIGNvbnRlP2RvIGRhIHRlc2Ugb3UgZGlzc2VydGE/P28gb3JhIGRlcG9zaXRhZGEuCgpDQVNPIEEgVEVTRSBPVSBESVNTRVJUQT8/TyBPUkEgREVQT1NJVEFEQSBURU5IQSBTSURPIFJFU1VMVEFETyBERSBVTSBQQVRST0M/TklPIE9VIApBUE9JTyBERSBVTUEgQUc/TkNJQSBERSBGT01FTlRPIE9VIE9VVFJPIE9SR0FOSVNNTyBRVUUgTj9PIFNFSkEgQSBTSUdMQSBERSAKVU5JVkVSU0lEQURFLCBWT0M/IERFQ0xBUkEgUVVFIFJFU1BFSVRPVSBUT0RPUyBFIFFVQUlTUVVFUiBESVJFSVRPUyBERSBSRVZJUz9PIENPTU8gClRBTUI/TSBBUyBERU1BSVMgT0JSSUdBPz9FUyBFWElHSURBUyBQT1IgQ09OVFJBVE8gT1UgQUNPUkRPLgoKQSBTaWdsYSBkZSBVbml2ZXJzaWRhZGUgc2UgY29tcHJvbWV0ZSBhIGlkZW50aWZpY2FyIGNsYXJhbWVudGUgbyBzZXUgbm9tZSAocykgb3UgbyhzKSBub21lKHMpIGRvKHMpIApkZXRlbnRvcihlcykgZG9zIGRpcmVpdG9zIGF1dG9yYWlzIGRhIHRlc2Ugb3UgZGlzc2VydGE/P28sIGUgbj9vIGZhcj8gcXVhbHF1ZXIgYWx0ZXJhPz9vLCBhbD9tIGRhcXVlbGFzIApjb25jZWRpZGFzIHBvciBlc3RhIGxpY2VuP2EuCg==Biblioteca Digital de Teses e Dissertaçõeshttps://tede.ufrrj.br/PUBhttps://tede.ufrrj.br/oai/requestbibliot@ufrrj.br||bibliot@ufrrj.bropendoar:2022-09-22T17:23:16Biblioteca Digital de Teses e Dissertações da UFRRJ - Universidade Federal Rural do Rio de Janeiro (UFRRJ)false |
dc.title.por.fl_str_mv |
Planejamento e s?ntese de compostos ftalazoilidraz?nicos como agentes anti-TNF-? |
dc.title.alternative.eng.fl_str_mv |
Planning and synthesis of phthalazoilidrazynic compounds aiming anti-TNF-? agents |
title |
Planejamento e s?ntese de compostos ftalazoilidraz?nicos como agentes anti-TNF-? |
spellingShingle |
Planejamento e s?ntese de compostos ftalazoilidraz?nicos como agentes anti-TNF-? Teixeira, F?bio Barbosa Ftalimidas atividade anti-TNF-? inflama??o Phthalimides anti-TNF-? activity inflammation Qu?mica |
title_short |
Planejamento e s?ntese de compostos ftalazoilidraz?nicos como agentes anti-TNF-? |
title_full |
Planejamento e s?ntese de compostos ftalazoilidraz?nicos como agentes anti-TNF-? |
title_fullStr |
Planejamento e s?ntese de compostos ftalazoilidraz?nicos como agentes anti-TNF-? |
title_full_unstemmed |
Planejamento e s?ntese de compostos ftalazoilidraz?nicos como agentes anti-TNF-? |
title_sort |
Planejamento e s?ntese de compostos ftalazoilidraz?nicos como agentes anti-TNF-? |
author |
Teixeira, F?bio Barbosa |
author_facet |
Teixeira, F?bio Barbosa |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
K?mmerle, Arthur Eugen |
dc.contributor.advisor1ID.fl_str_mv |
053.978.487-78 |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/5598000938584486 |
dc.contributor.referee1.fl_str_mv |
Graebin, Cedric Stephan |
dc.contributor.referee2.fl_str_mv |
Miranda, Leandro S. M. |
dc.contributor.authorID.fl_str_mv |
002.022.197-55 |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/0126796004403127 |
dc.contributor.author.fl_str_mv |
Teixeira, F?bio Barbosa |
contributor_str_mv |
K?mmerle, Arthur Eugen Graebin, Cedric Stephan Miranda, Leandro S. M. |
dc.subject.por.fl_str_mv |
Ftalimidas atividade anti-TNF-? inflama??o |
topic |
Ftalimidas atividade anti-TNF-? inflama??o Phthalimides anti-TNF-? activity inflammation Qu?mica |
dc.subject.eng.fl_str_mv |
Phthalimides anti-TNF-? activity inflammation |
dc.subject.cnpq.fl_str_mv |
Qu?mica |
description |
Many classes of organic compounds have shown promising biological effects, and among them are the cyclic imides, compounds that have on their structure the fragment CO-N(R)-CO-, in which R is a hydrogen atom, an alkyl or an aryl group. The phthalimides,that have recognized biological activity, are compounds related to thalidomide, a molecule with structure derived from phthalimide, but also presents a glutarim?dic group, being considered the most relevant molecule that belongs to this class of compounds. The phthalimidic ring is related as an interesting biophore, constituting a subunity structure of pharmacophore character for a series of compounds with different pharmacological activities, including the anti-inflammatory, according to a mechanism of inhibition of tumor necrosis factor alpha (TNF-?), a pro-inflammatory cytokine. Due to the side effects associated to current medications anti-TNF-?, that belong exclusively to the class of biotech drugs, and the high cost of treatment, the discovery of new anti-inflammatory micromolecules that act inhibiting the production of TNF-? is important. In this context, one of the first described molecules with this activity was thalidomide, whose pharmacological action is attributed to the phthalimidic group. in this work N-hydrazil substituted phthalimides, the phthalazoylidrazides were synthesized, charatered and tested for biological activity. These compounds were synthesized from benzoic acids and corresponding aldehydes, that were transformed into methyl esters. Subsequent hydrazinolysis reaction, with hydrazine hydrate, provided the corresponding hydrazides that, after, reacted with phthalic anhydride in order to form the phthalimidic ring. This initial series was still methylated by reaction with methyl iodide in basic medium. The synthesis of phthalazoylidrazides N-methylated and non-methylated intent to analyze the effect of the presence of the methyl group on the possible biological activity of the compounds, because it is known that the methyl group exerts estereoeletr?nic effects over biomolecules that can lead to significant changes in biological effects of molecules. 22 final compounds were synthesized with yields between 58% and 96%. The pharmacological analysis showed that some methylated derivatives were able to inhibit the production of TNF-? in experiments with macrophages stimulated by LPS. The activity presented shows the biological importance of phthalimides and N-methylation in this series. Furthermore, the synthesis proposal proved adequate and practical using microwave irradiation. |
publishDate |
2013 |
dc.date.issued.fl_str_mv |
2013-03-07 |
dc.date.accessioned.fl_str_mv |
2020-04-09T23:25:12Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
TEIXEIRA, F?bio Barbosa. Planejamento e s?ntese de compostos ftalazoilidraz?nicos como agentes anti-TNF-?. 2013. 192 f. Disserta??o (Mestrado em Qu?mica) - Instituto de Ci?ncias Exatas, Universidade Federal Rural do Rio de Janeiro, Serop?dica, 2013. |
dc.identifier.uri.fl_str_mv |
https://tede.ufrrj.br/jspui/handle/jspui/3428 |
identifier_str_mv |
TEIXEIRA, F?bio Barbosa. Planejamento e s?ntese de compostos ftalazoilidraz?nicos como agentes anti-TNF-?. 2013. 192 f. Disserta??o (Mestrado em Qu?mica) - Instituto de Ci?ncias Exatas, Universidade Federal Rural do Rio de Janeiro, Serop?dica, 2013. |
url |
https://tede.ufrrj.br/jspui/handle/jspui/3428 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.references.por.fl_str_mv |
Abbas, A., K.; Lichtman, A., H.; Pillai, S., (trad. Farias, A., S.); Imunologia Celular e Molecular, 6? ed., Elsevier, Rio de Janeiro, 2008. Akgun, H.; Karamelekoglu, I.; Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry: Recent Developments of Thalidomide Derivatives Possessing Anti-Inflammatory Activity, 9, 71-81, 2010. Akgun, H.; Karamelekoglu, I.; Berk, B.; Kurnaz, I.; Sarbyk, G.; Bioorg. Med. Chem: Synthesis and anti-mycobacterial activity of some phthalimide derivatives, 20, 4149-4154, 2012. Almeida, M. V.; Teixeira, F. M.; Souza de, M. V. N.; Amarante, G. W.; Alves, C. C. S.; Cardoso, S. H.; Mattos. A. M.; Ferreira, A. P.; Teixeria, H. C.; Chem Pharm Bull.: Thalidomide Analogs from Diamines: Synthesis and Evaluation as Inhibitors of TNF-? Production, 55, 2, 223-227, 2007. Andricopulo, A., D.; Filho, A., W.; Corr?a, R.; Santos, A., R., S.; Nunes, R., J.; Yunes, R., A.; Cechinel Filho, V.; Pharmazie, 53, 493, 1998. Antunes, R.; Batista, H.; Srivastra, R., M.; Thomas, G.; Ara?jo, C., C.; Bioorg. Med. Chem. Lett, 8, 3071, 1998. Back M. E.; Mandarino J. A. Fleischer?s glossary of Mineral Species. Tucson: The Mineralogical Record, 343. 2008. Barreiro, E.J.; Fraga, C.A.M. Qu?mica Medicinal: As Bases Moleculares da A??o dos F?rmacos, 2? edi??o, ARTMED, Porto Alegre, 2008. Barreiro. E.J. Estrat?gia de Simplifica??o Molecular no Planejamento Racional de F?rmacos: A Descoberta de Novo Agente Cardioativo, Quim. Nova, 25, 1172-1180, 2002. Blanchard, B. J.; Chen, A.; Rozeboom, L. M.; Stafford, K. A.; Weigele, P.; Ingram, V. M. Proc. Natl. Acad. Sci. U.S.A., 101, 14326, 2004. Buchanan, G.R.; Debaun, M.R.; Quinn, C.T.; Steinberg, H. Hematology: Sickle cell disease. 35-47, 2004. Burger, A. Burger?s Medicinal Chemistry, 4th ed, Willey, Nova York, 1980. Buzzi, F., C.; Corr?a, R.; Cechinel Filho, V.; In: Ci?ncias Farmac?uticas: Contribui??o ao desenvolvimentpo de novos f?rmacos e medicamentos, Itaja?: Univali, cap.2, p. 59-105, 2003. Campos, F., B.; Corr?a, R.; Cechinel Filho, V.; S?ntese de Mol?culas Bioativas: o exemplo das imidas c?clicas, In: Ci?ncias Farmac?uticas: Contribui??o ao desenvolvimentpo de novos f?rmacos e medicamentos, Itaja?: Univali, p. 57-105, 2000. Cechinel Filho, V.; Corr?a, R.; Nunes, R., J.; Calixto, J., B.; Yunes, R., A.; Pharm. Sci., 1, 399, 1995. Cechinel Filho, V.; Qu?m. Nova: Principais avan?os e perspectivas na ?rea de produtos naturais ativos: estudos desenvolvidos no NIQFAR/UNIVALI, 25 (3), p. 680-685, 2000. Cechinel Filho, V.; Campos, F. de; Yunes, R., A.; Corr?a, R.; Nunes, R., J.; Qu?m. Nova: Aspectos Qu?micos e Potencial Terap?utico de Imidas C?clicas: uma revis?o da literatura, V. 6, n? 2, p. 230-241, 2003. Chu, K. C.; The Basis of Medicinal Chemistry: The quantitative analysis of structure-activity- relationships, New York, Jonh Wiley, 393-418, 1980 Chudler, E., H.; Anderson, L., C.; Archives of Oral Biology: Behavioral and Eletrophisiological Consequences of deafferentation following chronic constriction of the infraorbital nerve in adult rats, v. 47, p. 165-172, 2002. Costa, B. B. C.; Corr?a, R.; Souza M. M. de; Pretto, J. B.; Ardenghi, J. V.; Campos-Buzzi, F. de; Cechinel-Filho, V.; Z Naturforsch: Antinociceptive Effects of Tetrahidrophthalimides and Related Compounds, 62, 201-206, 2007. Cotran, R., S.; Kumar, V.; Collins, T.; (trad. Barbosa, J., B.; De Vasconcelos, M., M.; Voeux, P., J.; Robbins ? Patologia Estrutural e Funcional, 6? ed., Guanabara Koogan, Rio de Janeiro, 2000. Coutaux, A.; Adam, F.; Willer, J., C.; Chelly, J., E.; Joint Bone Spine: Hyperalgesia and allodynia: peripheral mechanisms, v. 72, p. 359-371, 2005. Cunha, F., Q.; Br. J. Pharmacol.: Interleukine-8 as a mediator of symphatetic pain; v. 104, n?3, p. 765-767, 2000. Davies, F., E.; Raje, N., E.; Hideshima, T.; Lentzsch, S.; Young., G.; Tai, Y., T.; Lin, B.; Podar, K.; Gupta, D.; Chauhan, D.; Treon, S., P.; Richardson, P., G.; Schlossman, r., l.; Morgan, G., J.; Muller, G., W.; Stirling, D., I.; Anderson, K., C.; Blood, 98, 210, 2001. Decker L.; Ambrust W.; Rademaker C. M.; Prakken B.; Kuis W.; Wulffraat N. M.; Clin Exp Rheumatol: Safety of anti-TNF therapy in children with juvenile idiopathic arthritis, 22, 252-258, 2004. Dickenson, A., H.; Matthews, E., A.; Suzuki, R.; European Journalof Pain: Neurobiology of neuropathic pain: mode of action of anticonvulsants, v. 6, suplemento A, p. 51-60, 2002. Foeldvari, I.; Krueger, E.; Scneider, T.; Ann. Rheum. Dis.:Acute, non obstructive, steril colecystitis associated with etanercept and infliximab for the treatment of juvenile poliarticular rheumatoid arthritis, 62, 908-909, 2003. Furgeson, D., Y.; Dreher, M., R.; Chilkoti; J. Control. Rel.: Structural optimization of a ?smart? doxorubicin-poypeptide conjugate for thermally targeted delivery to solid tumors, v. 110, p. 362-369, 2006. Furler, R. L.; Uittenbogaart, C. H.; Immunologic Research: Signaling through the P38 and ERK pathways: Acommon link between HIV replication and the immune response, 48, 99-109, 2010. Hargreaves, M., K.; Pritchard, J., G.; Dave, H., R.; Chem. Rev., 70, 439, 1970. Hashimoto, Y.; Curr. Med. Chem, 5, 63, 1998. Hennessy, E. J.; Buchwald, S. L.; J. Org. Chem: Synthesis of 4,5-Dianilinophthalimide and Related Analogues for Potential Treatment of Alzheimer?s Disease via Palladium-Catalyzed Amination, 70, 7371-7375, 2005. Horvat, M.; Uzelac, L.; Marjanovic, M.; Cindro, N.; Frankovic, O.; Kralj, M.; Basaric, N.; Mlinaric-Majerski, K.; Chem Biol, Drug Des.: Evaluation of Antiproliferative Effect of N-(alkyladamantyl)phthalimides In Vitro, 79, 497-506, 2012. Iwai, Y.; Takahashi, H.; Hatakeyama, D.; Motoshima, K.; Ishikawa, M.; Sugita, K.; Hashimoto, Y.; Harada, Y.; Itamura, S.; Odagiri, T.; Tashiro, M.; Sei, Y.; Yamaguchi, K.; Kuzuhara, T.; Bioorg. Med. Chem.: Anti-influenza Activity of Phenetylphntylphthalimide analogs Derived from Thalidomide, 18, 5379-5390, 2010. Kaipiaienen-Seppanen, O.; Leino, M.; Ann Rheum. Dis.: Recurrent uveitis in a pacient with juvenile spondyloarthropathy associated with tumor necrosis factor alfa inhibitors, 62, 88-89, 2003. Kamal, A., Laxman, E., Rao, N. V., Tetrahedron Lett, 39, 8733, 1998. Kaminski, K.; Obniska, J.; Wiklik, B.; Atamanyuk, D.; Eur. J. Med. Chem.: Synthesis and Anticonvulsant Properties of New Acetamide Derivatives of Phthalimide, and its Saturated Ciclohexane and Norbornene Analogs, 46, 4634-4641, 2011. Kappe, C. O.; Stadler, A.; Microwaves in Organic and Medicinal Chemistry, Wiley-VHC, Weinheim, 2005. Kelsey, F., O.; Teratology, 38, 221, 1988. Komoda, M.; Kakuta, H.; Takahashi, H.; Fujimoto, Y.; Kadoya, S.; Kato, F.; Hashimoto, Y.; Bioorg. Med. Chem.: Specific inhibitor of puromycin-sensitive aminopeptidase with a hommophtalimide skeleton: identification of a target molecule and a strucuture- activity relationship study, 9 (1), p. 121-131, 2001. K?mmerle, A.E., Schmitt, M., Cardozo, S.V.S., Lugnier, C., Villa, P., Lopes, A.B., Romeiro, N.C., Justiniano, H., Martins, M.A., Fraga, C.A.M., Bourguignon, J.-J., Barreiro, E.J, J. Med. Chem: Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors, 7525-7545, 2012. K?mmerle, A.E., Raimundo, J.M., Leal, C.M., da Silva, G.S., Balliano, T.L., Pereira, M.A., de Simone, C.A., Sudo, R.T., Zapata-Sudo, G., Fraga, C.A.M., Barreiro, E.J., Eur. J. Med. Chem.:Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives, 44, 4004-4009, 2009. Lakowicz, J. R. In Principles of Fluorescence Spectroscopy, 2? ed., Kluwer Academic/Plenum Publishers, New York, 1999. Lanaro, C.; Franco-Penteado, C. F.; Albuquerque, D. M.; Saad, S. T.; Conran, N.; Costa, F. F; Biol.: Altered Levels of cytokines and inflammatory mediators in plasma and lecocytes of sickle cell anemia patients and effects of hydroxyurea therapy, 85, 2, 235-242, 2009. Lenz, W.; Lancet, 1, 271, 1962. Lima L. M. Planejamento, s?ntese e avalia??o farmacol?gica de novos candidatos ? prot?tipos de f?rmacos antiinflamat?rios e antiasm?ticos . [Tese] Rio de Janeiro: Instituto de Qu?mica, Universidade Federal do Rio de Janeiro, 2001. Lima L. M.; Castro P.; Machado A. L.; Fraga C. A. M.; Lugnier C,; Moraes V. L. G.; Barreiro E. J.; Bioorg Med Chem: Synthesis and anti inflamatory activity of phtalimide derivates, designed as new thalidomids analogues,10, 3067-3073, 2002. Lima L. M.; Fraga C. A. M.; Koatz, V. L. G.; Barreiro E. J.; Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry: Thalidomide and Analogs as Anti-Inflammatory and Immunomodulator Drug Candidates, 5, 79-95, 2006. Lovell, D., J.; Giannini, H., E.; Reiff, A.; Arthritis Reum.: long term efficacy anfd safety of etanercept in children with poliarticular course juvenile rheumatoid arthritis, 48, 218-226, 2003. Lima, P.C.; S?ntese e Avalia??o das propriedades Antinociceptivas de Novas Acilidrazonas Derivadas do Safrol, Rio de Janeiro, 1998. Disserta??o (Mestrado em Qu?mica Org?nica)-IQ, UFRJ, 1998. Luengo, M., B.; Rev. Eletr?n. Farm., 2, 64, 2005. Machado, A., L.; Lima, L., M.; Ara?jo-Jr; Bioorg. Med. Chem: Designing, synthesis and Antiinflamatory activity of novel phtalimide derivatives, structurally related to thalidomide, v. 15, p. 1169-1172, 2005. Madigan; Raj; Br. Med.: Post traumatic pain syndromes, v. 288, p. 169-170, 2000. Malav?, I.; Perdomo, Y.; Escalona, E.; Rodriguez, E.; Anchustegui, M.; Malav?, H. Acta Haematol: Level of Tumor Necrosis Factor alpha/cachectin (TNF alpha) in sera from patients with sickle cell disease. v. 90, 172-176, 1993. McBride, W., G.; Lancet, 2, 1358, 1961. Mellin, G. W.; Katzenstein, M.; Engl .J. Med.: The Saga of Thalidomide, 267, 1184-1193, 1962. Menegatti, R.; Fraga, C., A., M.; Barreiro, E. J.; Quim. Nova Escola: A import?ncia da s?ntese de f?rmacos, 3, p. 16-22, 2001. Neves P. C. P. das; Schenato F.; Bachi F. A. Introdu??o ? Mineralogia Pr?tica. Canoas, ULBRA, 326, 2008. Newman, D. J.; Cragg, G. M.; Snader, K. M.; J. Nat. Prod: Natural Products as Sources of New Drugs over the Period 1981-2002, 66, 1022-1037, 2003. Oh, S.; Kim, J. S.; Hwang, J. H.; Lee, H. Y.; Ryu, M. J.; Park, J.; Kim, S. J.; Jo, Y. S.; Kim, Y. K.; Lee, C.; Kweon, K. R.; Shong, M.; Park, S. B.; J. Med. Chem.: Antidiabetic and Antiobesity Effects of Ampikinone (6f), a Nove Smalll Molecule Ativator of AMP-Actuvated Protein Kinase, 53, 7405-7413, 2010. Olsen, N., J.; Stein., M., C.; New Eng. J.Med.: New drus for Rheumatoid Arthritis, 350, 2167-2179, 2004. Otani, Y.; Nagae, O.; Naruse, Y.; Inagaki, S.; Ohno, M.; Yamaguchi, K.; Yamamoto, G.; Uchiyama, M.; Ohwada, T.; J. Am. Chem. Soc: An Evaluation of Amide Group Planarity in 7-Azabicyclo[2.2.1]heptane Amides. Low Amide Bond Rotation Barrier in Solution, 125, 15191-15199, 2003. Pathare, A.; Kindi, S. A.; Daar, S.; Dennison, D.; Hematology: Cytokines in sickle cell disease, 8, 5, 329-337, 2003. Pfizenmaier, K.; Wajant, H.; Grell, M.; Cytokine Growth Factor Rev., 7, 22, 1996. Poli, G.; Kinter, A.; Justement, J. S.; Proc. Nat. Acad. Sci : Tumor Necrosis Factor Alpha functions in an Autocrine Manner in the Induction of Human Immunodeficiency Virus Expression, 87, 782-785, 1990. Poupaert, J., H.; Gaetane, H.; Barbeaux, P.; Lambert, D.; Henichart, J.; Pharmacology, 47, 89, 1995. Quartier, P.; Taupin, P.; Bourdeaut, F, et al; Arthritis Rheum.: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the Onset Type, 48, 93-101, 2003. Raje, N.; Anderson, K.; New England J. Med., 341, 1606, 1999. Ramanan, A., V.; Scheneder, R.; J. Rheumatol: Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile arthritis, 30, 401-403, 2003. Rang, H., P.; Dale, M., M.; Ritter, J., M.; Flower, R., J. (trad. Do Nascimento, A., P.); Farmacologia, 6? ed., Elsevier, Rio de Janeiro, 2007. Rendall, T., J.; Am. J. Med. Assoc., 263, 1467, 1990. Saldanha, P. H.; Rev.Bras. Genet.: A Trag?dia da Talidomida e o Advento de Teratologia Experimental, 17, 4, 449-464, 1994. Sampaio, E., P.; Zmuidinas, A.; Frindt, P.; Smith, K., A.; Kaplan, G.; J. Exp. Med., 177, 1675, 1993. Seri-Levy, A.; Richards, G.; Tetrahedron Asymmetry, 4, 1917, 1993. Sheskin, J.; Clin. Pharm. Ther., 6, 303, 1965. Shibata, Y., Sasaki, K.; Nishimura, K.; Hashimoto, Y.; Iwasaki, S.; Biol. Pharm. Bull., 17, 1532, 1994. Shibata, Y.; Sasaki, K.; Hashimoto, Y.; Iwasaki, S.; Biol. Pharm. Bull., 18, 1228, 1995. Silverman, R., B.; The Organic Chemistry of Drug Design and Drug Action, 2nd ed., Ed., Elsevier Academic Press, San Diego, 2004. Solomons, C. T. W.; Fryhle, C. B.; Qu?mica Org?nica, LTC editora,Rio de Janeiro, 2000. Sthepens, M., C.; Shepanski, M., A.; Mamula, P.; Markowitz, J., E.; Brown, K., A.; Baldassano, R., N.; Am. J. Gastroenterol., 98, 104-111, 2003. Tamura, F.; Volgesang, G. B.; Reitz, B. A.; Baumgartner, W. A.; Herskovitz, A.; Transplantation: Combination Thalidomide and Ciclosporine for Cardiac Allograft Rejection, 49, 20-25, 1990. Teixeira, F. B. S?ntese ?one-pot?, em microondas, de N-metilidrazidas como intermedi?rios de produtos bioativos. Rio de Janeiro, 2010, Monografia, ICE-DQ, UFRRJ, 2010. Tsuji, M.; Koiso, Y.; Takahashi, H.; Hashimoto, Y.; Endo, Y.; Biol. Pharm. Bull., 23, 513, 2000. Tutar, E.; Eriki, F.; Na?ar, N.; Arici, S.; Atalay, S.; Rheumatology, 43, 674-675, 2004. Tweedie, D.; Luo, W.; Short, R., G.; Brossi, A.; Holloway, H., W.; Li, Y.; Yu, Q., S.; Greig, N., H.; J. Neurosci. Meth.: A cellular model of inflammation for identifying TNF-alphasynthesis inhibitors, 183, 182-187, 2009. Verschuren W.G., Dierynck I., Amssoms K. I. E., Hu L., Boonants P. M. J. G., Pille G. M. E., Daeyert F. F. D., Hertogs K , Surleraux D. L. N. G, Wigerinck P. B. T. P. . J Med.Chem.: Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase, 48(6):1930-1940, 2005. Volgesang, G. B.; Wells, M. C.; Santos, G. W.; Chen T. L.; Hess, A. D.; Transplant Proc.: Combination Low-dose Thalidomide and Ciclosporine Prophylaxis for Acute Graft-versus-Host-Disease iin Rat Mismatched Model, 20, 226-228, 1988. Warkany, J.; Year Med. Book Pub.:Congenital Malformations (Notes and Comments), Chicago, 49-129, 1971. Weiberg, K.; Acc Chem. Res.: The Interaction of Carbonil Groups with Substituents, 32, 922-929, 1999. Wermuth, C., G; The Practice of Medicinal Chemistry, Ed., Academic Press, Londres, 2008. Wermuth, C.G. & Langer, T.; Pharmacophore identification, em 3D QSAR in Drug Design. Theory Methods and application, Kubinyi, H., Ed., ESCOM, Leiden, pp. 117-136, 1993. Wettstein, A. R.; Meagher, A. P.; Lancet: Thalidomide in Chron`s Disease,350, 1445-1446, 1997. Yamada, S.; Morizono, D.; Yamamoto, K. Tetrahedron Lett: Mild Oxidation of Aldehydes to the Coresponding Carboxylic Acids and Esters: Alkaline Iodine Oxidation Revisited, 33, 4329-4332, 1992. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal Rural do Rio de Janeiro |
dc.publisher.program.fl_str_mv |
Programa de P?s-Gradua??o em Qu?mica |
dc.publisher.initials.fl_str_mv |
UFRRJ |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
Instituto de Ci?ncias Exatas |
publisher.none.fl_str_mv |
Universidade Federal Rural do Rio de Janeiro |
dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações da UFRRJ instname:Universidade Federal Rural do Rio de Janeiro (UFRRJ) instacron:UFRRJ |
instname_str |
Universidade Federal Rural do Rio de Janeiro (UFRRJ) |
instacron_str |
UFRRJ |
institution |
UFRRJ |
reponame_str |
Biblioteca Digital de Teses e Dissertações da UFRRJ |
collection |
Biblioteca Digital de Teses e Dissertações da UFRRJ |
bitstream.url.fl_str_mv |
http://localhost:8080/tede/bitstream/jspui/3428/8/2013+-+F%C3%A1bio+Barbosa+Teixeira.pdf.jpg http://localhost:8080/tede/bitstream/jspui/3428/6/2013+-+F%C3%A1bio+Barbosa+Teixeira.pdf http://localhost:8080/tede/bitstream/jspui/3428/3/2013+-+Fabio+Barbosa+Teixeira.pdf.txt http://localhost:8080/tede/bitstream/jspui/3428/7/2013+-+F%C3%A1bio+Barbosa+Teixeira.pdf.txt http://localhost:8080/tede/bitstream/jspui/3428/1/license.txt |
bitstream.checksum.fl_str_mv |
5ac00e5dadea4a97435967a50f95959c b329ffba7061b0158a4f1fae7d46dbc9 e0d3e99cd599c6168d530961343a90af 378d4a30e599f29fa54a651742682ace 7b5ba3d2445355f386edab96125d42b7 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Biblioteca Digital de Teses e Dissertações da UFRRJ - Universidade Federal Rural do Rio de Janeiro (UFRRJ) |
repository.mail.fl_str_mv |
bibliot@ufrrj.br||bibliot@ufrrj.br |
_version_ |
1797220307478511616 |